Join us in-person in San Diego, CA for the BioProcess Int. US West event. Learn more about our involvement in the event below.
Just - Evotec Biologics at BioProcess Int. US West 2026
Summary of Our Participation
Presentations
Metabolomic Characterization of a Perfusion Bioprocess System Improves Culture Performance
Date and Time: Tuesday, 10th March, 11:45am
Presenter: Erin Weisenhorn, Senior Scientist II, Mass Spectrometry, Just - Evotec Biologics
You will hear:
- What to monitor in CHO perfusion to protect viability and yield
- Where metabolomics (incl. ML enabled quantitation) fits in real workflows
- A media optimization case study showing improved day 14 viability in a perfusion context
Introducing J.Media™: A Next Generation Perfusion Medium for CHO Cell Culture
Date and Time: Tuesday, 10th March, 1:40pm - 1:50 pm
Location: Innovation & Community Stage
Presenter: Jon Gunther, VP Business Development Biologics US West Coast, Just - Evotec Biologics
Panel Discussion
In addition to her individual presentation, Erin Weisenhorn is scheduled to participate in an expert panel discussion alongside representatives from Pfizer, BeOne Medicines, Regeneron, and Novasign. This panel will explore how automation, AI, and novel platforms will reshape cell line development (CLD) by 2030.
Date: Tuesday, 10th March
Poster Presentations
Evaluation of Red One™ Workflow to Detect Bioburden Contaminations in CHO Cell Supernatant Within 24 Hours
Bioburden is analyzed to detect the presence of microorganisms; routine analysis of bioburden is critical to ensure product safety and efficacy. Traditional methods of bioburden testing utilize tryptic soy agar (TSA) and sabouraud dextrose agar (SDA) plates with 5 or 7 days of incubation to allow macroscopic colonies to form and allow for visual examination of colony formation. These lengthy times-to-result can lead to waste in process and prolonged release of drug-substance.
Solid phase cytometry (SPC) using the Red One™ offers an alternative method for detecting microorganisms down to the single cell level by measuring esterase activity in viable cells. This method allows for expedited results in 24 hours. In this study, SPC was shown to selectively detect activity of gram positive bacteria, gram negative bacteria and mold in the presence and absence of CHO cell matrix. Three different microorganisms, known to affect biologic production, (Table 1) were used to show non inferiority in specificity and limit of detection of the SPC method to traditional TSA and SDA methods.
Presenter by David Ferrer, Senior Associate Scientist, Cell Line Development, Just - Evotec Biologics
Fully Automated High Throughput Perfusion Screening to Accelerate J.Media™ Optimization and Clone Selection for Biologics Development
Chinese Hamster Ovary (CHO) perfusion processes can deliver higher productivity and more consistent product quality than traditional fed batch processes, but realizing these benefits requires careful selection of optimal clone and media combination. Early stage screening can be performed using batch or fed batch formats, yet these conditions only provide indirect insight into how CHO cells will behave in perfusion systems. These indirect comparisons limit confidence in media or clone selection, and scale up takeaways are similarly constrained. While perfusion systems such as 3L benchtop bioreactors, the ambr®15, and ambr®250 can generate more representative at-scale production data, their high cost and limited throughput make them impractical for large design screens within a short timeframe. Manual plate assays that mimic perfusion are also challenging to execute consistently due to labor intensive daily operations. To address these limitations, Just - Evotec Biologics developed the Automated Mock Perfusion (AMP) platform: a fully automated, high throughput system capable of screening large numbers of media and clone conditions under semi continuous perfusion like operation. The AMP enables broad exploration of both media and clone design spaces using workflows that are more consistent and relevant of true perfusion conditions than traditional screening approaches.
Presented by Jonathan Mene, Scientist II, Media Development & Services, Just - Evotec Biologics
